Annual report pursuant to Section 13 and 15(d)

COH Agreements (Details Textual)

v3.7.0.1
COH Agreements (Details Textual) - USD ($)
 1 Months Ended 10 Months Ended 12 Months Ended
Feb. 28, 2017
Mar. 17, 2015
Dec. 31, 2015
Dec. 31, 2016
Mar. 13, 2017
Dec. 30, 2015
Research and Development Expense     $ 1,500,000 $ 2,000,000    
Stock Issued During Period, Value, Issued for Services     $ 147,000 $ 862,000    
Common Stock, Shares Subscribed but Unissued     250,000 767,264    
Research and Development Asset Acquired Other than Through Business Combination, Fair Value Acquired       $ 4,400,000    
Common Stock, Shares, Outstanding     2,000,000 15,165,244    
Stephen Forman [Member]            
Annual Consulting Fees       $ 60,000    
Christine Brown [Member]            
Annual Consulting Fees       60,000    
Fortress Biotech, Inc [Member]            
Research and Development Asset Acquired Other than Through Business Combination, Fair Value Acquired     $ 190,000 $ 4,400,000    
Fortress Biotech, Inc [Member] | Common Stock [Member]            
Shares Issued, Price Per Share     $ 0.147      
Stock Issued During Period, Value, Issued for Services     $ 36,750      
Common Stock, Shares Subscribed but Unissued       2,000,000    
Fortress Biotech, Inc [Member] | Subsequent Event [Member]            
Shares Issued, Price Per Share         $ 5.73  
City Of Hope [Member]            
Payment Of Upfront Fees   $ 2,000,000        
Stock Issued During Period, Shares, Other   1,000,000        
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners   10.00%        
Marketability Percentage Of Invested Capital   44.80%        
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent   30.00%        
Share Price   $ 0.147        
Stock Issued During Period, Value, Other   $ 147,000        
Research And Development Expense, Sponsored Research Payment   $ 2,000,000        
City Of Hope [Member] | Subsequent Event [Member]            
Stock Issued During Period, Shares, Purchase of Assets 293,588          
Shares Issued, Price Per Share $ 5.73          
Proceeds from Issuance of Common Stock $ 1,700,000          
Fair Value Assumptions, Expected Volatility Rate 77.00%          
Fair Value Assumptions, Risk Free Interest Rate 1.93%          
Third Party Investors [Member] | Subsequent Event [Member]            
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners 10.00%          
Proceeds from Issuance of Common Stock $ 10,000,000          
Preferred Class A [Member] | Fortress Biotech, Inc [Member]            
Share Price       $ 5.73    
Common Stock, Shares Subscribed but Unissued       767,264    
Common Class A [Member]            
Stock Issued During Period, Value, Issued for Services     $ 0 $ 0    
Common Stock, Shares, Outstanding     1,000,000 1,000,000    
Noncontrolling Interest, Ownership Percentage by Parent       6.10%   10.00%